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Abstract
Background: We previously showed that mice exposed to cigarette smoke for three weeks exhibit loss of bone marrow B
cells at the Pro-B-to-pre-B cell transition, but the reason for this is unclear. The antioxidant N-acetylcysteine (NAC), a
glutathione precursor, has been used as a chemopreventive agent to reduce adverse effects of cigarette smoke exposure on
lung function. Here we determined whether smoke exposure impairs B cell development by inducing cell cycle arrest or
apoptosis, and whether NAC treatment prevents smoking-induced loss of developing B cells.
Methodology/Principal Findings: Groups of normal mice were either exposed to filtered room air or cigarette smoke with
or without concomitant NAC treatment for 5 days/week for three weeks. Bone marrow B cell developmental subsets were
enumerated, and sorted pro-B (B220
+CD43
+) and pre-B (B220
+CD43
2) cell fractions were analyzed for cell cycle status and
the percentage of apoptotic cells. We find that, compared to sham controls, smoke-exposed mice have ,60% fewer pro-B/
pre-B cells, regardless of NAC treatment. Interestingly, NAC-treated mice show a 21–38% increase in total bone marrow
cellularity and lymphocyte frequency and about a 2-fold increase in the pro-B/pre-B cell subset, compared to sham-treated
controls. No significant smoking- or NAC-dependent differences were detected in frequency of apoptotic cells or the
percentage cells in the G1, S, or G2 phases of the cycle.
Conclusions/Significance: The failure of NAC treatment to prevent smoking-induced loss of bone marrow pre-B cells
suggests that oxidative stress is not directly responsible for this loss. The unexpected expansion of the pro-B/pre-B cell
subset in response to NAC treatment suggests oxidative stress normally contributes to cell loss at this developmental stage,
and also reveals a potential side effect of therapeutic administration of NAC to prevent smoking-induced loss of lung
function.
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Introduction
Cigarette smoking is known to adversely impact innate and
adaptive immunity through its pro-inflammatory and immuno-
suppressive effects on host defense systems [1]. Most studies
investigating the effects of smoking on the immune system are
understandably focused on those components localized to the
respiratory and circulatory system, as they are most directly
affected by the compounds and particulates present in cigarette
smoke. However, we have recently shown that developing B cells
in the bone marrow are also affected by cigarette smoking: mice
exposed to a mixture of mainstream and sidestream smoke for
three weeks showed a significant reduction in the percentage of
bone marrow B220
+CD43
2 B cells (which includes pre-B,
immature, and mature B cells), but not B220
+CD43
+ B cells
(which includes pre/pro-B and pro-B/pre-B cells) [2]. Cessation of
smoking for six weeks largely reversed this outcome [2]. How and
why B cells at this developmental stage are negatively affected by
cigarette smoke exposure is unclear.
The pathological effects of cigarette smoking are thought to be
mediated in part by oxidative stress that is caused both from the
oxidants present in cigarette smoke [3], and the reactive oxygen
species produced by leukocytes activated in response to smoking
[4]. The role of oxidative stress in smoking-induced pathologies
has prompted efforts to investigate whether compounds with anti-
oxidant properties can be used therapeutically to counteract the
oxidative stress associated with cigarette smoke exposure [5]. N-
acetylcysteine (NAC) is a molecule that possesses anti-oxidant
properties through its ability to directly neutralize reactive oxygen
species (ROS) via interactions with its free thiol, and its indirect
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protecting against endogenous and exogenous sources of oxidative
stress [5]. NAC has been used in both animal models and humans
to ameliorate the effects of smoking on lung function [5]. NAC has
also been used to counteract the effects of ROS that are thought to
contribute to immunological senescence. Specifically, NAC
administration in a murine model of premature aging [6] and in
elderly women [7] has been reported to enhance lymphocyte
chemotaxis and proliferation, but suppress lymphocyte adherence
ex vivo. The effects of NAC treatment on lymphocyte development
were not reported in these experiments. We therefore wished to
test whether NAC administered during a smoke exposure regimen
in mice could counteract the negative effects of smoking on B cell
development under these conditions. We also sought to determine
whether the loss of bone marrow B220
+CD43
2 B cells observed in
mice exposed to cigarette smoke could be attributed to a smoking-
induced arrest of cell cycle or an increase in apoptosis in this cell
population.
Consistent with previous results, we found that smoking had the
largest adverse effect (2-fold reduction) on developing B cells
that are immunophenotypically defined as B220
+AA4.1
+CD43
2
CD19
+CD24
+sIgM
2sIgD
2, which includes pro-B and pre-B cells.
We found that NAC treatment unexpectedly expanded the
baseline levels of this pro-B/pre-B cell subset by about 2-fold,
but did not attenuate the smoking-induced loss of this population.
No significant effects of smoking on apoptosis or the cell cycle
status of B220
+CD43
+ or B220
+CD43
2B cells was detected.
Taken together, these data argue against oxidative stress as being a
direct cause of smoking-induced loss of developing B cells.
However, the unanticipated observation that NAC promotes
expansion of pro- and pre-B cells indicates that developing B cells
are normally lost through pathways activated in response to
oxidative stress, and also reveals a potential side effect of
therapeutic NAC administration to ameliorate smoking-induced
pathologies.
Results
Overview of experimental design
Wild-type adult C57BL/6 mice were divided into four
treatment groups (n=10–12 mice/group) in which animals
received PBS or 100 mg/kg NAC in PBS and were then exposed
to filtered air or a mixture of mainstream and sidestream cigarette
smoke for 3 hrs. This regimen was repeated 5 days/week for three
weeks as summarized in Figure 1A (sham/sham, NAC/sham,
sham/smoke, and NAC/smoke, respectively). The duration of
smoke exposure was chosen based on our previous study which
demonstrated that mice exposed to cigarette smoke for three weeks
showed a significant decrease in bone marrow B220
+CD43
2 B
cells (which includes pre-B, immature B, and mature B cell
subsets), but earlier precursor B220
+CD43
+ B cells (which includes
pre/pro-B and pro-B subsets) and splenic transitional and mature
B cells were not significantly affected by smoke exposure [2]. The
route and dose of NAC administered to the animals was chosen
based on studies showing that this treatment regimen was sufficient
to reverse smoking-induced effects in other systems [8,9]. When
the experiment was completed, urine was collected to measure
cotinine and creatine levels, and animals were euthanized and
bone marrow harvested for B cell isolation and/or analysis using
multicolor flow cytometry. The smoking procedure produced a
mean value for the total suspended particles of 101632 mg/m
3
and a cotinine/creatine ratio of 11396317 ng/mg 18 h after the
last smoke exposure. Since the half-life of cotinine of 16 h [10],
doubling the ratio to reflect the cotinine level immediately after
smoke exposure yields a value that is .40-fold higher than the
mean ratio observed in urine samples collected from human
passive smokers, and is roughly equivalent to a moderate smoker
who smokes 10–20 cigarettes/day [11].
Consistent with our previous results [2], total bone marrow
cellularities and the total number of cells within a lymphocyte gate
(defined based on the forward and side scatter gating strategy
shown in Fig. 1B) were not significantly different between sham/
sham and sham/smoke groups (Fig. 1C, Table 1). This was also
true when NAC/sham and NAC/smoke groups were compared to
each other. Unexpectedly, however, both NAC/sham and NAC/
smoke groups showed a significant increase (27–38%) in total bone
marrow cellularity compared to the sham/sham and sham/smoke
groups. A similar, but smaller (21–36%) increase in the total
number of cells within the lymphocyte gate was also observed, but
the differences were only statistically significant when comparing
the sham/smoke and NAC/smoke groups.
To enumerate B cells within various bone marrow develop-
mental subsets, we originally intended to identify subsets based on
differential B220 and CD43 staining as described previously [2].
However, the anti-CD43 antibody was inadvertently omitted from
the antibody cocktail for one set of samples (representing 3–4
mice/treatment group). As a result, the experiment was under-
powered for statistical analysis using CD43 as a marker. Despite
this shortcoming, we nevertheless observed a substantial reduction
in the mean number of developing bone marrow B220
+CD43
2 B
cells in mice from the sham/smoke compared to the sham/sham
group, whereas smoke exposure had smaller effect on the number
of cells within the B220
+CD43
+ subset (Fig. S1). Similar results
were obtained when NAC/sham and NAC/smoke groups were
compared (Fig. S1). However, we also concomitantly stained for
AA4.1, a marker that can be used as an alternative to CD43 to
identify progenitor B cell populations with reportedly similar
results [12]. Therefore, we used B220 and AA4.1 to segregate B
cells into two populations, B220
+AA4.1
+ and B220
+AA4.1
2
(Fig. 2A, top row). Contaminating cells expressing DX5
+, CD4
+,
and Ly6C were excluded from both populations, and sIgM
+ and
sIgD
+ cells were additionally excluded from the B220
+AA4.1
+
subset [12]. Based on differential expression of CD19 and CD24,
the B220
+AA4.1
+ population was further resolved into pre/pro-B
(CD192CD24
2) and pro-B/pre-B (CD19
+CD24
+) subsets
(Fig. 2A, middle row). The B220
+AA4.1
2 population, in turn,
was subdivided based on differential sIgM and sIgD expression
into pre-B (IgM
2IgD
2), immature (IgM
+IgD
2), and mature
(IgM
+IgD
+) subsets (Fig. 2A, bottom row).
When sham/sham and sham/smoke treatment groups were
compared, mice in the latter group were found to have about
50% fewer B cells in the B220
+AA4.1
+ fraction (p=0.045), which
was traced to a selective and significant reduction (,60%) in the
pre-B/pro-B (CD19
+CD24
+) subset (p=0.037). The number of
cells within each of the other developmental subsets analyzed was
not significantly different between these treatment groups (Fig. 2B
and Table 1). Interestingly, when sham/sham and NAC/sham
groups were compared, we found that the latter mice showed a
significant 2-fold increase in the number of cells within the
B220
+AA4.1
+ population, which was again specifically traced to
expansion of the pre-B/pro-B (CD19
+CD24
+) subset. By
contrast, the absolute number of B220
+AA4.1
2 B cells was
slightly diminished (but not significantly) in NAC/sham mice
compared to sham/sham mice. However, within this subset, we
observed a ,2-fold increase in immature B cells (p,0.001), but
this was offset by a 36% decrease in mature B cells (p,0.028).
Interestingly, when NAC/sham and NAC/smoke groups were
compared, we found that smoke exposure in NAC-treated
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as well as later subsets, as it did in animals receiving PBS only.
Taken together, these results show that smoke exposure has a
striking adverse effect on a pro-B/pre-B cell population, defined
as B220
+AA4.1
+CD19
+CD24
+IgM
2IgD
2, and that concomitant
NAC treatment does not negate the smoking-induced loss of this
B cell subset, but does increase the frequency of these cells
independent of smoke exposure.
Figure 1. Total bone marrow and lymphocyte cellularities are increased by NAC treatment, but not smoke exposure. (A) Animals were
divided into four groups and subjected to the treatments indicated. For additional details on experimental dosing, see Materials and Methods. (B)
Bone marrow cells were analyzed by flow cytometry and a population with low forward scatter (FSC) and side scatter (SSC) properties enriched for
viable lymphocytes was gated (Lymph+ gate). A representative plot is shown for an animal in each treatment group. (C) Mean values for the total
bone marrow and gated lymphocyte cell counts were calculated for each of the experimental groups. Statistically significant differences (p,0.05) are
indicated.
doi:10.1371/journal.pone.0024804.g001
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cells may be caused by an arrest of cell cycle progression or an
induction of apoptosis following smoke exposure. To test these
possibilities, we relied on our conventional strategy using B220 and
CD43 staining. B220
+CD43
+ and B220
+CD43
2 B cells were
sorted by FACS (Fig. 3A), and stained with either Annexin V and
propidium iodide to evaluate the frequency of early and late
apoptotic cells (defined as staining positive for Annexin V and
either negative [early] or positive [late] for propidium iodide,
respectively), or stained with Vindelov’s reagent to examine the
cell cycle status of sorted cells (Fig. 3B). We found that neither
B220
+CD43
+ B cells nor B220
+CD43
2 B cells purified from mice
in the sham/sham and sham/smoke groups showed any significant
difference in the percentage of apoptotic cells or cells in the G1, S,
or G2 phases of the cell cycle between treatment groups (Fig. 3C).
Given this outcome, we considered the possibility that smoking
might negatively impact proliferating B cells that represent a small
fraction of this pro-B/pre-B cell subset more so than other cells
within this population, and therefore the effects of smoking on cell
cycle might be masked in this analysis. To investigate this
possibility, we re-plotted the gated the B220
+AA4.1
+IgM
2IgD
2
population to visualize B220 staining versus forward scatter as an
indicator of cell size (Fig. 4A). The B cells with high forward scatter
(FSC) profile detected in this plot represent large pre-B cells
expressing pre-BCR and are undergoing proliferative expansion
[13]. We then reanalyzed the effects of NAC treatment and smoke
exposure on B220
+ cells within this population that were
segregated based on a low or high FSC profile. We found that
smoke exposure and NAC treatment had similar outcomes on
both low and high FSC subsets that mirrored the effects observed
in the B220
+AA4.1
+IgM
2IgD
2population overall (Fig. 4B).
Discussion
In a previous study, we found that normal mice exposed to a
mixture of mainstream and sidestream smoke for three weeks
showed a significant reduction (,50%) in the percentage of bone
marrow B220
+CD43
2 B cells, but earlier B220
+CD43
+ B cell
progenitors and splenic transitional and mature B cell subsets were
not significantly affected by this smoking regimen [2]. Using a
slightly different gating strategy, we have now further refined the
developmental stage at which smoking affects B cell development,
showing that three weeks of smoke exposure causes a significant
and selective ,60% reduction of B cells in a developmental subset
that is phenotypically characterized as B220
+AA4.1
+CD19
+C-
D24
+IgM
2IgD
2 which includes pro-B and early pre-B cells.
Other earlier and later developmental stages were not significantly
affected by smoke exposure. These results contrast subtly to our
earlier finding that the B220
+CD43
+ B cell subset, which also
includes pro-B cells, was not significantly reduced by smoke
exposure [2]. Since CD43 is known to be expressed on B cell
developmental subsets that concomitantly express B220, AA4.1,
CD19, and CD24 [14], we re-examined whether smoke exposure
differentially affected B220
+AA4.1
+CD19
+CD24
+IgM
2IgD
2 cells
that were either CD43
+ or CD43
2 within the group of animals in
which cells were properly stained with both CD43 and AA4.1.
Consistent with previous results [2], those in the sham/smoke and
NAC/smoke group showed a selective reduction in the CD43
2
fraction of these cells compared to their non-smoked counterparts.
However, because of insufficient power (as discussed in the results),
the differences were only statistically significant when comparing
NAC/sham and NAC/smoke groups (Fig. S2).
We also tested whether the smoking-induced loss of developing B
cellscouldbe attributed toaltered cellcycleprogressionorincreased
apoptosis.Although we didnotfind any significantdifferences inthe
frequency of cells in the various phases of the cell cycle or the
percentage ofcellsundergoing apoptosisbetween sham- andsmoke-
exposed mice at the time when the animals were euthanized for
analysis (which was 18 hours after the last smoking treatment), we
cannot rule out the possibility that in vivo effects of smoke exposure
on cellcycle and apoptosisin B cells are induced earlier than we had
analyzed. Future experiments will address this possibility.
Because NAC has been investigated as a potential anti-oxidant
therapy to attenuate the effects of smoking on lung function [5],
Table 1. Summary of total cell counts of various B cell subsets (610
5 unless indicated).
Bone Marrow
Sham/
Sham
Sham/
Smoke
NAC/
Sham
NAC/
Smoke
ONE
WAY
ANOVA
a
Sham/
Sham vs.
Sham/
Smoke
b
Sham/
Sham vs.
NAC/
Sham
b
Sham/
Smoke vs.
NAC/
Smoke
b
NAC/
Sham vs.
NAC/
Smoke
b
(n=10) (n=11) (n=11) (n=12)
Cellularity (610
7) 2.8660.21 2.7760.20 3.6260.26 3.8560.33 {{ n.s. n.s. {{ n.s.
Lymphs (610
5)1 1 7 681 0 8 661 4 2 691 3 9 611 { n.s. n.s. { n.s.
Lymph
+Ly6C
2DX5
2CD4
2
B220
+AA4.1
+ 14.662.4 6.861.2 29.663.4 16.062.6 {{{ { {{{ { {{{
Pre/Pro B and Pro-B
(CD19
2CD24
2IgM
2IgD
2)
1.1160.16 1.0160.07 1.2360.27 1.1460.21 n.s. n.s. n.s. n.s. n.s.
Pro-B/Pre-B
(CD19
+CD24
+IgM
2IgD
2)
9.9661.85 4.1260.91 21.062.4 11.562.0 {{{ { {{{ {{ {{{
Lymph
+Ly6C
2DX5
2CD4
2
B220
+AA4.1
2 10.961.2 9.5960.71 9.3560.71 8.3261.03 n.s. n.s. n.s. n.s. n.s.
Pre- B (IgM
2IgD
2) 3.5960.33 3.1260.14 3.8760.26 3.8260.34 n.s. n.s. n.s. n.s. n.s.
Imm. B (IgM
+IgD
2) 0.5460.07 0.4760.04 1.0560.09 0.7360.09 {{{ n.s. {{{ { {{{
Mature B (IgM
+IgD
+) 6.5360.96 5.7860.62 4.1560.52 3.5660.68 { n.s. {{ n.s.
aVariance between groups by one-way ANOVA: n.s., not significant; {, p#0.05; {{, p#0.01; {{{, p#0.005.
bPost-hoc analysis by unpaired t test: n.s., not significant; {, p#0.05; {{, p#0.01; {{{, p#0.005.
doi:10.1371/journal.pone.0024804.t001
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24804we hypothesized that NAC treatment in mice could protect
developing B cells from the adverse effects of smoking. However,
we did not find this to be the case, but found unexpectedly that
NAC-treated mice showed a significant (,2-fold) increase the
absolute number of B cells in the pro-B/pre-B cell
(B220
+AA4.1
+CD19
+CD24
+IgM
2IgD
2) subset (Fig. 2B), especial-
ly the CD43
2 fraction of these cells (Fig. S2), which is the same
subset adversely affected by cigarette smoke exposure. This result
suggests that the mechanism of smoking-induced loss of the pro-B/
pre-B cell subset does not involve a direct response to oxidative
stress in these cells, but may instead be a secondary consequence of
the activation of pathways involved in this response in other cells.
However, the observation that NAC treatment significantly
increases the abundance of pro-B/pre-B cells in the absence of
smoking suggests that oxidative stress normally contributes to the
loss of cells within this developmental subset. During the window
from pro-B to pre-B cell development, cells may encounter
oxidative stress as they undergo apoptosis [5] or proliferation [13]
in response to unproductive or productive heavy chain gene
rearrangement. Although not specifically tested in developing B
cells, NAC has been shown to inhibit apoptosis and potentiate
proliferation in cell culture. Specifically, Rosati et al. reported that
NAC inhibits the spontaneous apoptosis of human tonsillar B
lymphocytes in vitro by inhibiting the processing of caspase-3 and -
7 [15], and De la Fuente et al. showed that NAC enhanced the
proliferation of leukocytes stimulated with concavalin A in vitro
[16]. Since the number of B220
+AA4.1
+sIgM
2sIgD
2 B cells with
low and high FSC profiles are both increased by NAC treatment,
the evidence suggests NAC treatment does not uniquely affect an
actively proliferating B cell subset (Fig. 4B). Determining how
NAC promotes expansion of pro-B/pre-B cells in mice will be a
focus of future investigations.
Because NAC is being investigated for therapeutic use, one
implication of this study is that patients treated with NAC
treatment may show evidence of bone marrow lymphocytosis. The
physiological consequences of this potential side effect are unclear
Figure 2. NAC treatment does not ameliorate the adverse effects of smoking on B cell development, but causes a smoking-
independent 2-fold increase in the pro-B/pre-B cell subset. (A) Animals in the treatment groups indicated above the panel were analyzed for
the expression of B220 and AA4.1 (top row), CD19 and CD24 (middle row), or sIgM and sIgD (bottom row) on bone marrow cells identified by the
gating parameters shown below each row. Developmental subsets specified by the staining pattern are indicated at right with corresponding gates.
The percentage of cells within the identified gate is shown for representative animals. (B) The absolute number of cells within each developmental
subset identified in (A) was calculated for the animals in each treatment group (see Table 1). The mean values for each data set are plotted in bar
graph format. Statistically significant differences between treatment groups (p,0.05) are indicated.
doi:10.1371/journal.pone.0024804.g002
Figure 3. Apoptosis and cell cycle status in the B220
+CD43
+ and B220
+CD43
2 B cell subsets are not significant altered by smoke
exposure. (A) B220
+CD43
+ and B220
+CD43
2 B cells were purified by FACS in the sham/sham and sham/smoke treatment groups (pre- and post-sort
analysis, top row), and immediately stained with annexin V (AV) and propidium iodide (PI) (middle row) to identify early [AV
+PI
2] or late [AV
+PI
+]
apoptotic cells or necrotic cells [AV
2PI
+], or stained with Vindelov’s reagent (bottom row) to analyze cell cycle status. The percentage of cells within
each quadrant or cell cycle phase is shown. Results are representative of 3–5 independent experiments. (B) Mean values for the data collected in
panel A are plotted in bar graph format (C). No statistically significant differences between treatment groups were identified.
doi:10.1371/journal.pone.0024804.g003
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progress to subsequent stages of development may be limited by
the physical availability of niches to support their continued
maturation. However, if NAC is shown to promote survival of
developing B cells by inhibiting apoptosis, this situation may
enable B cells with unrepaired V(D)J recombination-induced DNA
breaks to survive long enough to permit illegitimate and possibly
oncogenic rearrangements.
Materials and Methods
Animals and experimental conditions
The animal research protocol described here was approved by
the Creighton University Institutional Animal Care and Use
Committee (investigator: D.M.C.; protocol number 882). Adult
(4–5 month old) normal female C57BL/6 mice were weighed and
randomized into four treatment groups (n=10–12 mice). Animals
were injected intraperitoneally with either PBS or 100 mg/kg
NAC (10% solution, Roxane Laboratories, Columbus OH). Two
hours later, animals were exposed to either room air or a mixture
of mainstream and sidestream cigarette smoke derived from
burning Kentucky 3R4F reference cigarettes (Tobacco and Health
Research Institute, University of Kentucky) using a TE-10
smoking device (Teague Enterprises, Davis, CA) for 3 hours as
previously described [2]. These treatments were performed 5
days/week for three weeks. The average total suspended particle
(TSP) level created by this smoking regimen was 101632 mg/m
3.
Urine was collected 18 h after the final treatment and cotinine and
creatine levels were measured by ELISA as previously described
[2]. Animals were then euthanized and bone marrow was collected
and prepared for cell analysis or sorting using flow cytometry.
Flow cytometry
Bone marrow cell suspensions were prepared as previously
described [2], and stained with a cocktail containing the following
mouse-specific antibodies obtained from BD Biosciences (San Jose,
CA), eBioscience (San Diego, CA), or Southern Biotech (Birming-
ham, AL): FITC-anti-IgD (11-26c.2a); PE-Texas Red-anti-B220
(RA3-6B2); PE-CD93 (AA4.1); APC-anti-IgM (II/41); Alexa-
fluor700-anti-CD4 (GK1.5), SpectralRed anti-CD24 (30-F1);
Figure 4. NAC treatment expands the number of both small and large B cells in the pro-B/pre-B cell subset. (A) The FSC profile of bone
marrow B cells with a Lymph
+Ly6C
2DX5
2CD4
2B220
+AA4.1
+sIgM
2sIgD
2 immunophenotype were analyzed from animals in the indicated treatment
groups. The percentage of B220
+ cells within the low and high FSC gate is shown for representative animals. (B) Collected data is summarized as
described in Figure 2B.
doi:10.1371/journal.pone.0024804.g004
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APC-Cy7 anti-CD19 (1D3), and biotin anti-CD43 (S7). Biotiny-
lated antibodies were revealed using a streptavidin conjugate to
QDot 585 (Invitrogen, Carlsbad, CA). FACS was used to isolate
B220
+CD43
+ and B220
+CD43
2 B cells from bone marrow
preparations pooled from two animals within each of the sham/
sham and sham/smoke treatment groups. Sorted cells were
immediately analyzed for apoptosis by staining with Annexin V
and propidium iodide using a commercially available kit according
to the manufacturer’s instructions (BD Biosciences), and evaluated
for cell cycle status by with propidium iodide according to the
method of Vindelov [17]. All flow cytometric data was analyzed
using FlowJo (TreeStar, Ashland, OR) or ModFit LT (Verity
Software, Topsham, ME).
Supporting Information
Figure S1 Effects of smoking and/or NAC treatment on
B cells subsets identified by staining with B220 and
CD43. This shows the B220 vs CD43 staining profiles for bone
marrow lymphocytes, and the calculated frequencies of
B220
+CD43
+sIgM
2sIgD
2 and B220
+CD43
2 B cell subsets for
animals in the four treatment groups.
(DOCX)
Figure S2 Smoke exposure and NAC treatment have
differential effects on the CD43
+ and CD43
2 fractions of
the B220
+AA4.1
+sIgM
2sIgD
2CD19
+CD24
+ pro-B/pre-B
cell subset. This shows the calculated frequencies of the
CD43
+ and CD43
2 fractions of the B220
+AA4.1
+sIgM
2-
sIgD
2CD19
+CD24
+ pro-B/pre-B cell subset for animals in the
four treatment groups.
(DOCX)
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